Transfusion-Dependent Anemia After Initiation of Androgen Deprivation Therapy for Metastatic Prostate Cancer
| Autor: | Rajiv K. Pruthi, Kelly K. Curtis, Rafael Fonseca, Michael K. Gornet |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
Oncology medicine.medical_specialty Blood transfusion Antineoplastic Agents Hormonal Anemia Urology medicine.medical_treatment Adenocarcinoma Metastasis Androgen deprivation therapy Hemoglobins Prostate cancer Internal medicine medicine Humans Blood Transfusion Testosterone Aged business.industry Prostatic Neoplasms Cancer Androgen Antagonists medicine.disease Discontinuation Surgery Telangiectasia Hereditary Hemorrhagic Leuprolide Gastrointestinal Hemorrhage business |
| Zdroj: | Urology. 70:811.e5-811.e8 |
| ISSN: | 0090-4295 |
| DOI: | 10.1016/j.urology.2007.07.030 |
| Popis: | Androgen deprivation therapy (ADT) is a commonly used treatment for metastatic prostate cancer. A 78-year-old patient with metastatic prostate cancer had transfusion-dependent anemia develop while on ADT. The patient also had hereditary hemorrhagic telangiectasia (HHT), with chronic gastrointestinal blood loss. Blood transfusions were required every 3 weeks for 4 months to keep hemoglobin levels above 8 g/dL, despite discontinuation of ADT. The anemia, which had been well managed with iron therapy before ADT, was worsened by the loss of bone marrow-stimulating testosterone effects. The case highlights testosterone's important role in erythrocyte production. Practitioners should monitor hemoglobin levels in patients undergoing ADT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect